GB201818110D0 - Monocytes for cancer targeting - Google Patents

Monocytes for cancer targeting

Info

Publication number
GB201818110D0
GB201818110D0 GBGB1818110.7A GB201818110A GB201818110D0 GB 201818110 D0 GB201818110 D0 GB 201818110D0 GB 201818110 A GB201818110 A GB 201818110A GB 201818110 D0 GB201818110 D0 GB 201818110D0
Authority
GB
United Kingdom
Prior art keywords
monocytes
cancer targeting
targeting
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1818110.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macrophox Ltd
Original Assignee
Macrophox Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrophox Ltd filed Critical Macrophox Ltd
Priority to GBGB1818110.7A priority Critical patent/GB201818110D0/en
Publication of GB201818110D0 publication Critical patent/GB201818110D0/en
Priority to PCT/GB2019/053140 priority patent/WO2020095044A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1818110.7A 2018-11-06 2018-11-06 Monocytes for cancer targeting Ceased GB201818110D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1818110.7A GB201818110D0 (en) 2018-11-06 2018-11-06 Monocytes for cancer targeting
PCT/GB2019/053140 WO2020095044A1 (en) 2018-11-06 2019-11-06 Monocytes for cancer targeting

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1818110.7A GB201818110D0 (en) 2018-11-06 2018-11-06 Monocytes for cancer targeting

Publications (1)

Publication Number Publication Date
GB201818110D0 true GB201818110D0 (en) 2018-12-19

Family

ID=64655458

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1818110.7A Ceased GB201818110D0 (en) 2018-11-06 2018-11-06 Monocytes for cancer targeting

Country Status (2)

Country Link
GB (1) GB201818110D0 (en)
WO (1) WO2020095044A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
JP2022546592A (en) 2019-09-03 2022-11-04 マイエロイド・セラピューティクス，インコーポレーテッド Methods and compositions for genomic integration
IL293718A (en) * 2019-12-11 2022-08-01 Myeloid Therapeutics Inc Therapeutic cell compositions and methods for manufacture and uses thereof
EP4240367A4 (en) 2020-11-04 2024-10-16 Myeloid Therapeutics Inc Engineered chimeric fusion protein compositions and methods of use thereof
GB202019108D0 (en) * 2020-12-03 2021-01-20 Ospedale San Raffaele Srl Vector
KR20240013094A (en) 2021-03-17 2024-01-30 마이얼로이드 테라퓨틱스, 인크. Engineered chimeric fusion protein compositions and methods of using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2286819A1 (en) * 1997-04-17 1998-10-22 Flossie Wong-Staal Use of lentiviral vectors for antigen presentation in dendritic cells
WO2007113572A1 (en) * 2006-04-03 2007-10-11 Keele University Targeted therapy
WO2012005763A1 (en) * 2010-07-06 2012-01-12 The Scripps Research Institute Use of myeloid-like progenitor cell populations to treat tumors
CA2903096A1 (en) * 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
CA2979835A1 (en) * 2015-03-17 2016-09-22 Tilt Biotherapeutics Oy Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
JP6959909B2 (en) * 2015-09-09 2021-11-05 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） Genetic recombination of macrophages for immunotherapy

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
AHN G-O ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 18, May 2010 (2010-05-01), pages 8363 - 8368
AZIZI ET AL., CELL, vol. 174, August 2018 (2018-08-01), pages 1293 - 1308
COBOS-JIMENEZ ET AL., PHYSIOL GENOMICS, vol. 46, 2014, pages 91 - 103
DVORAK, NEW ENGLAND J MEDICINE, vol. 315, no. 26, 1986, pages 1650 - 9
ELLIOT ET AL., FRONTIERS IN IMMUNOLOGY, vol. 8, 2017
FRANKLIN; AND LI, TRENDS CANCER, vol. 2, no. 1, 2016, pages 20 - 34
FRASER ET AL., CYTOTHERAPY, vol. 19, no. 9, September 2017 (2017-09-01), pages 1113 - 1124
MILLER ET AL., SCIENCE TRANSLATIONAL MEDICINE, vol. 9, no. 392, 2017
MUHLEBACH ET AL., MOLECULAR THERAPY, vol. 12, no. 6, 2005, pages 1206 - 16
NATURE METHODS, vol. 5, no. 1, 2008, pages 16 - 18
SHIAO SL ET AL., CANCER IMMUNOL RES., vol. 3, no. 5, pages 518 - 525

Also Published As

Publication number Publication date
WO2020095044A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
IL271946A (en) Combination cancer therapy
IL254705B (en) Combination therapy for cancer
EP3368656A4 (en) Targeted cancer therapy
IL287644A (en) Cytarabine conjugates for cancer therapy
GB201818110D0 (en) Monocytes for cancer targeting
ZA202005847B (en) Cancer therapy
HK1258387A1 (en) Targeting mda-5 activation for cancer immunotherapy
EP3733175A4 (en) Cancer therapeutic
IL282093A (en) Combination therapy for cancer
IL292272A (en) Cancer vaccine
EP3391885A4 (en) Therapeutic agent for breast cancer
EP3675891A4 (en) Combination cancer therapy
EP3256115A4 (en) Combination cancer therapy
EP3576746A4 (en) Cancer therapeutic
GB201814487D0 (en) Cancer
GB201800733D0 (en) Cancer
GB201913957D0 (en) Cancer
GB2580963B (en) Cancer therapies
GB201704909D0 (en) Cancer therapy
GB201703907D0 (en) Novel therapies for cancer
HK1254687A1 (en) Combination therapy for cancer
GB201711855D0 (en) Cancer therapy
EP3344287A4 (en) Anti-survivin antibodies for cancer therapy
GB201901991D0 (en) Cancer
IL282030A (en) Antibodies targeting epn1

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)